Norges Bank
NPCE icon

Norges Bank’s Neuropace NPCE Stock Holding History

Norges Bank’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-58,000
Closed -$476K – 2128
2022
Q1 		$476K Hold
58,000
– – ﹤0.01% 2103
2021
Q4 		$585K Hold
58,000
– – ﹤0.01% 2141
2021
Q3 		$919K Hold
58,000
– – ﹤0.01% 2154
2021
Q2 		$1.38M Buy
+58,000
New +$1.35M ﹤0.01% 2062

Other funds holding NPCE

KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM

Norges Bank's NPCE Position: Q2 2022 in Review

Norges Bank sold out of Neuropace (NPCE) in Q2 2022, closing a stake of 58,000 shares — an estimated $476K sold.

Norges Bank first reported a position in NPCE in Q2 2021 and held it in 4 quarters. The position peaked at $1.38M in Q2 2021. 32 funds tracked by Wall St. Rank hold NPCE as of Q2 2022.

  • Norges Bank reported no remaining Neuropace position as of Q2 2022 after selling out during the quarter.
  • Norges Bank sold 58,000 Neuropace shares in Q2 2022, an estimated $476K.
  • Norges Bank first reported a position in Neuropace in Q2 2021 and held it in 4 quarters.
  • Norges Bank's Neuropace position peaked at $1.38M in Q2 2021.
  • 32 funds tracked by Wall St. Rank held Neuropace as of Q2 2022.

Based on Norges Bank's 13F filing for Q2 2022, filed 11 Aug 2022.